Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1, Journal of Clinical Investigation, vol.118, issue.9, pp.3132-3174, 2008. ,
DOI : 10.1172/JCI35700DS1
Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome, JAMA, vol.313, issue.15, pp.1550-63, 2015. ,
DOI : 10.1001/jama.2015.3253
A Modified ??-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency, New England Journal of Medicine, vol.371, issue.15, pp.1407-1424, 2009. ,
DOI : 10.1056/NEJMoa1404588
Transfusion independence and HMGA2 activation after gene therapy of human ??-thalassaemia, Nature, vol.6, issue.7313, pp.318-340, 2010. ,
DOI : 10.1093/nar/gkn125
URL : https://hal.archives-ouvertes.fr/cea-00905288
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy, Science, vol.116, issue.11, pp.818-841, 2009. ,
DOI : 10.1172/JCI28873
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome, Science, vol.177, issue.10, p.1233151, 2013. ,
DOI : 10.4049/jimmunol.177.10.7451
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy, Science, vol.9, issue.3, p.1233158, 2013. ,
DOI : 10.1002/(SICI)1098-1004(1997)9:3??234::AID-HUMU4??3.0.CO;2-7
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med, 2006. ,
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes, Science, vol.298, issue.5594, pp.850-854, 2002. ,
DOI : 10.1126/science.1076514
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, vol.114, issue.3, pp.535-581, 2009. ,
DOI : 10.1182/blood-2009-03-211714
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response, Clinical Cancer Research, vol.21, issue.5, pp.1019-1046, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2708
LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1, Science, vol.302, issue.5644, pp.415-424, 2003. ,
DOI : 10.1126/science.1088547
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B, New England Journal of Medicine, vol.371, issue.21, pp.1994-2004, 2014. ,
DOI : 10.1056/NEJMoa1407309
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells, Blood, vol.121, issue.12, pp.2224-2257, 2013. ,
DOI : 10.1182/blood-2012-10-460733
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, New England Journal of Medicine, vol.371, issue.16, pp.1507-1524, 2014. ,
DOI : 10.1056/NEJMoa1407222
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, The Lancet, vol.385, issue.9967, pp.517-545, 2015. ,
DOI : 10.1016/S0140-6736(14)61403-3
The future of immune checkpoint therapy, Science, vol.19, issue.5, pp.56-61, 2015. ,
DOI : 10.1158/1078-0432.CCR-12-1630
Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery, Nat Biotechnol, 2007. ,
in Autologous CD4 T Cells of Persons Infected with HIV, New England Journal of Medicine, vol.370, issue.10, pp.901-911, 2014. ,
DOI : 10.1056/NEJMoa1300662
A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models, Cell Stem Cell, vol.12, issue.2, pp.238-51, 2013. ,
DOI : 10.1016/j.stem.2012.11.011
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science, pp.993-999, 2011. ,
Enrichment of G2/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases, Scientific Reports, vol.339, issue.1, p.21264, 2016. ,
DOI : 10.1126/science.1231143
Chimeric Nucleases Stimulate Gene Targeting in Human Cells, Science, vol.300, issue.5620, p.763, 2003. ,
DOI : 10.1126/science.1078395
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity, Science, vol.274, issue.45, pp.816-837, 2012. ,
DOI : 10.1074/jbc.274.45.31896
Therapeutic genome editing: prospects and challenges, Nature Medicine, vol.122, issue.2, pp.121-152 ,
DOI : 10.1126/science.332.6033.1031
Genome engineering using the CRISPR-Cas9 system. Nature Protocols, pp.2281-308, 2013. ,
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell, pp.1380-1389, 2013. ,
Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells, Hepatology, vol.40, issue.6, pp.2458-68, 2013. ,
DOI : 10.1093/nar/gks518
TALEN-based Gene Correction for Epidermolysis Bullosa, Molecular Therapy, vol.21, issue.6, p.2013 ,
DOI : 10.1038/mt.2013.56
Transcription Activator-like Effector Nuclease (TALEN)-mediated Gene Correction in Integration-free ??-Thalassemia Induced Pluripotent Stem Cells, Journal of Biological Chemistry, vol.258, issue.48, pp.34671-34680, 2013. ,
DOI : 10.1038/nbt.1940
Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation, STEM CELLS, vol.3, issue.5, pp.1470-1479 ,
DOI : 10.5966/sctm.2013-0054
UROPORPHYRINOGEN III COSYNTHETASE IN HUMAN CONGENITAL ERYTHROPOIETIC PORPHYRIA, Proceedings of the National Academy of Sciences, vol.63, issue.3, 1969. ,
DOI : 10.1073/pnas.63.3.856
C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria, Annals of Human Genetics, vol.62, issue.3, pp.225-255, 1998. ,
DOI : 10.1046/j.1469-1809.1998.6230225.x
Point mutations in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria (Günther's disease). Blood, pp.1763-1768, 1990. ,
Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene., Journal of Clinical Investigation, vol.89, issue.2, pp.693-700, 1992. ,
DOI : 10.1172/JCI115637
Porphyrias Consortium of the NIH- Sponsored Rare Diseases Clinical Research Network. Congenital Erythropoietic Porphyria, GeneReviews(®) [Internet] ,
Protéine p53 : de l'interaction avec les protéines virales à la pathogénie des cancers humains, Virologie, vol.2, pp.347-54, 1998. ,
Genetic screens in human cells using the CRISPR-Cas9 system. Science, pp.80-84, 2014. ,
Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9, Stem Cell Reports, vol.4, issue.1, pp.143-54, 2015. ,
DOI : 10.1016/j.stemcr.2014.10.013
Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects, Nature Methods, vol.11, issue.4, pp.399-402 ,
DOI : 10.1093/bioinformatics/btq033
Rationally engineered Cas9 nucleases with improved specificity, Science, vol.520, issue.25, pp.84-92, 2016. ,
DOI : 10.1038/nature14299
Gene Therapy in a Patient with Sickle Cell Disease, New England Journal of Medicine, vol.376, issue.9, pp.848-55, 201702. ,
DOI : 10.1056/NEJMoa1609677